Who We are
Cellix is an innovative drug design and development Biopharmaceutical Company founded on May 21, 2014 is focused to develop best-in-class therapies for the treatment of Neurological, Inflammatory and Metabolic Diseases. Using our proprietary technologies and strong scientific platform “Synergix”; new and effective medicines are being developed that modulate more than one target in the disease pathway while minimizing as much risk as possible from the discovery and development process. We select drugs known for their demonstrated efficacy and clinical safety along the targeted biological pathway, and use our proprietary synergix technology platform to produce new medicines that modulate the disease pathway with enhanced safety and efficacy profile.
Our Science Team
Mahesh Kandula, Drug Design and Development, IP Matters
Mahesh brings over >11 years of scientific and entrepreneurial experience in the life science industry. Mr. Kandula has been named an inventor on 36 United States Issued Patents, 29 United States Patent Applications and 100 International Patent Applications. Mr. Kandula received his Master of Technology degree from IIT Kharagpur.
Ashok Rampal., M.Pharm - Formulation development
Ashok Rampal has more than 3 decades of experience in R & D management and formulation development in renowned companies like Knoll Pharmaceuticals, Ranbaxy-Lilly, Ranbaxy Research Labs and Alkem Labs Ltd. Mr. Rampal hold Master’s degree in Pharmaceutics from Panjab University and Diploma in Business Management from Mumbai. He is inventor in more than 110 patent applications.
K.B. Sunil Kumar, PhD., Non -clinical
Specialized in Pharmaceutical Toxicology with >22 years of professional experience in Drug Discovery and development. Experienced in the development of preclinical strategy, target product profile, drug target assessment and risk assessment.
Sivanesan P, DABT., Non-clinical
Sivanesan has > 11 years of experience in nonclinical development of various pharmaceutical products. Experienced in planning and conducting nonclinical studies for new chemical entities and evaluating the safety profile of a drug candidate in various therapeutic areas. He is a certified Diplomate of American Board of Toxicology.